Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZSFree Report) (TSE:AEZ) in a research note published on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their target price on shares of Aeterna Zentaris from $28.00 to $15.00 and set a buy rating for the company in a report on Monday, November 13th.

View Our Latest Stock Report on Aeterna Zentaris

Aeterna Zentaris Trading Up 5.6 %

Aeterna Zentaris stock opened at $1.79 on Friday. The firm has a 50 day moving average of $1.97 and a 200 day moving average of $2.15. The firm has a market capitalization of $8.69 million, a price-to-earnings ratio of -0.37 and a beta of 1.57. Aeterna Zentaris has a 12-month low of $1.36 and a 12-month high of $3.69.

Aeterna Zentaris (NASDAQ:AEZSGet Free Report) (TSE:AEZ) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.24). Aeterna Zentaris had a negative return on equity of 49.10% and a negative net margin of 340.56%. On average, analysts predict that Aeterna Zentaris will post -3.22 EPS for the current year.

Aeterna Zentaris Company Profile

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Articles

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.